NCM
OCUL icon

Nantahala Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Nantahala Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-437,728
Closed -$3.74M – 156
2024
Q4 		$3.74M Sell
437,728
-262,272
-37% -$2.56M 0.16% 94
2024
Q3 		$6.09M Sell
700,000
-300,000
-30% -$2.47M 0.31% 62
2024
Q2 		$6.84M Buy
+1,000,000
New +$6.17M 0.4% 47

Other funds holding OCUL

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's OCUL Position: Q1 2025 in Review

Nantahala Capital Management sold out of Ocular Therapeutix (OCUL) in Q1 2025, closing a stake of 437,728 shares — an estimated $3.74M sold.

Nantahala Capital Management first reported a position in OCUL in Q2 2024 and held it in 3 quarters. The position peaked at $6.84M in Q2 2024. 196 funds tracked by Wall St. Rank hold OCUL as of Q1 2025.

  • Nantahala Capital Management reported no remaining Ocular Therapeutix position as of Q1 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 437,728 Ocular Therapeutix shares in Q1 2025, an estimated $3.74M.
  • Nantahala Capital Management first reported a position in Ocular Therapeutix in Q2 2024 and held it in 3 quarters.
  • Nantahala Capital Management's Ocular Therapeutix position peaked at $6.84M in Q2 2024.
  • 196 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2025.

Based on Nantahala Capital Management's 13F filing for Q1 2025, filed 15 May 2025.